ADAPNASDAQHealthcare · Biotechnology

Adaptimmune Therapeutics plc

$0.05-3.00%($-0.00)

TickerSpark Score

65/100

Solid

Valuation

Profitability

100

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADAP research report →

52-Week Range3% of range

Low $0.02

Current $0.05

High $0.86

Companywww.adaptimmune.com

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers.

CEO: Adrian G. Rawcliffe
IPO: 2015
Employees: 506
HQ: Abingdon, GB

Price Chart

-93.59% · this period

Valuation

Market Cap: $75.16M
P/E: -0.03
P/S: 0.16
P/B: -0.06
EV/EBITDA: -0.19
Div Yield: 0.00%

Profitability

Gross Margin: 86.02%
Op Margin: -618.34%
Net Margin: -629.09%
ROE: 472.78%
ROIC: -169.54%

Growth & Income

Revenue: $178.03M · 195.34%
Net Income: $-70,814,000 · 37.81%
EPS: $-0.28 · 50.42%
Op Income: $-68,760,000
FCF YoY: 47.91%

Performance & Tape

52W High: $0.86
52W Low: $0.02
50D MA: $0.10
200D MA: $0.26
Beta: 2.49
Avg Volume: 110.64M

Get TickerSpark's AI analysis on ADAP

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime